CELL INTELLIGENCE · 肿瘤细胞治疗研究

免疫效应细胞相关肠炎的组织学谱系与 T 细胞克隆性特征

Characterization of Histologic Spectrum and T-Cell Clonality in Immune Effector Cell-Associated Enteritis.

靶向 BCMA 和 GPRC5D 的双特异性抗体治疗浆细胞白血病的真实世界结局

Real-world outcomes with BCMA- and GPRC5D-targeting bispecific antibodies in plasma cell leukemia.

原发性浆细胞白血病

Primary Plasma Cell Leukemia.

CAR-T 细胞治疗后的 B 细胞缺乏：发生率、动力学、预后意义与临床管理

B Cell Aplasia Following CAR T Cell Therapy: Incidence, Kinetics, Prognostic Implications, and Clinical Management.

我如何治疗浆细胞白血病

How I treat plasma cell leukemia.

原发性浆细胞白血病患者首次进展后的进展模式与临床结局

Patterns of Progression and Clinical Outcomes After First Progression in Patients With Primary Plasma Cell Leukemia.

cilta-cel 与靶向 BCMA 的双特异性抗体在复发/难治性多发性骨髓瘤中的真实世界结局

Real-world outcomes of cilta-cel versus BCMA-targeting bispecific antibodies in relapsed/refractory multiple myeloma.

接受抗 CD38 与 BCMA 治疗的多发性骨髓瘤患者中巨细胞病毒再激活的前瞻性研究

Prospective Study of Cytomegalovirus Reactivation in Patients With Multiple Myeloma Receiving Anti-CD38 and BCMA Therapies.

在接受靶向 CD38 和 BCMA 药物的 MM 患者中，低水平 CMV 检出较为常见，但病毒血症通常具有自限性，在我们的研究队列中，尽管 CMV 检出率相对较高，却没有出现有症状的 CMV 感染。

CAR 疗法在肿瘤与自身免疫领域的演进：机制见解与治疗创新

The evolution of CAR therapies across oncology and autoimmunity: mechanistic insights and therapeutic innovations.

多发性骨髓瘤对 BCMA 靶向 CAR-T 细胞疗法的耐药：生物学、临床模式与克服治疗失败的策略

Resistance to BCMA-Directed CAR T-Cell Therapy in Multiple Myeloma: Biology, Clinical Patterns, and Strategies to Overcome Treatment Failure.